Overview
Key Takeaways
- Tirzepatide activates two hormone receptors (GIP and GLP-1) while semaglutide activates one, and trials show greater average weight loss with tirzepatide
- Rapid weight loss on either medication can cause facial volume loss, commonly called Ozempic face
- The right choice depends on your health history, tolerance, and goals, and should be made with a qualified physician
As weight loss medications become more effective, patients are asking a sharper question: not just how much weight they can lose, but how those changes will reshape their overall appearance. The Tirzepatide vs Semaglutide conversation has evolved beyond a clinical comparison; it’s now a decision about how the body and the face transform over time.
Both medications belong to a newer generation of injectable therapies that regulate appetite and metabolism. They share a foundation, but their mechanisms and outcomes can diverge in ways that matter clinically and aesthetically.